Skip to main content
. 2019 Feb 12;14(2):e0212053. doi: 10.1371/journal.pone.0212053

Fig 5. Sensitization of melanoma and prostate cancer cells to DDA but not IFN-γ.

Fig 5

A-B) Validation of SLFN11 KD by western blot in DU145 (A) and WM2664 (B). C-D) DU145 (C) and WM2664 cells (D) transduced with a control lentiviral vector or with independent SLFN11-targeting shRNA were exposed to the indicated concentrations of IFN-γ. 7 days after IFN-γ exposure, cell viability was assayed by analysis of metabolic activity. E-H) DU145 (E, G) and WM2664 (F, H) cells transduced with a control lentiviral vector or with independent vectors encoding SLFN11-targeting shRNA were exposed to the indicated concentrations of cisplatin (E, F) or doxorubicin (G, H). 48 hours after exposure, cell viability was assayed by analysis of metabolic activity. I-J) DU145 (I) and WM2664 (J) cells that were either untreated or pre-incubated for 1 h with Q-VD-OPh (10μM) were exposed to the indicated concentrations of IFN-γ. 7 days after IFN-γ exposure, cell viability was assayed by analysis of metabolic activity. * p<0.05, ** p<0.01, *** p<0.001.